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ABSTRACT
MICRORNA REGULATION AND CELLULAR PROTEOSTASIS IN PARKINSON’S
DISEASE
Alberim Kurtishi

Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder
predominately affecting the aging population. It is the second most common
neurodegenerative disorder after Alzheimer’s disease (AD) affecting over 1 million
individuals in the US alone. Recent studies have tried to understand the exact nature in
which healthy neurons transition to a degenerative state in PD. There are a multitude of
combinatory factors that can lead to the development of PD including environmental
factors, genetic factors, and aging. The majority of PD cases are sporadic in nature,
however familial cases account for 5-10% of total PD cases world-wide. The hallmark
feature of PD is the formation of Lewy bodies, abnormal protein aggregates enriched in
the protein -synuclein (a-syn) in dopaminergic neurons of the substantia nigra. These
aggregates affect the overall protein homeostasis (proteostasis) in neurons causing
deleterious effects. The lack of accurate diagnostic biomarkers clearly represents a
challenge for PD patients and their caregivers.
It has become increasingly apparent that microRNAs (miRNA), key regulators of
gene expression, are involved in numerous disease processes including PD. We
investigated miR-335-5p and miR-3613-3p, two microRNAs previously reported by our
laboratory, to be significantly up-regulated in serum samples of PD patients as compared
to healthy age-matched controls. We also corroborated those findings when we extracted

RNA from frontal cortex tissue of PD patients and age-matched controls finding that
miR-335-5p, miR-3613-3p, and miR-6865-3p were all significantly upregulated in
patients with PD. Using mass spectrometry and in silico prediction methods we identified
a number of potential protein targets for both miR-335-5p and miR-3613-3p. Using
several molecular approaches, we found that three proteins involved in PD pathogenesis
are regulated by miR-335-5p and miR-3613-3p, respectively. Ataxin-3 (ATXN3), BCL2
Associated athanogene 5 (BAG5), and Autophagy related 5 (ATG5) are all proteins
targeted and regulated by both miR-335-5p and miR-3613-3p. miR-335-5p and miR3613-3p have not previously been characterized for their potential biological roles with
respect to neurodegeneration or neuroprotection. In this study we further dissect the
neuroprotective role of both miR-335-5p and miR-3613-3p in cells induced with stress.
Our results significantly contribute to our understanding of PD and the contributing
factors to neurodegeneration.
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Introduction
1.1. Parkinson’s Disease
Neurodegenerative disorders such as Parkinson’s disease (PD), Alzheimer’s disease
(AD), Huntington’s disease (HD), and Amyotrophic lateral sclerosis (ALS) are all caused
by neuronal dysfunction and cell death. Neurodegeneration is a complex process often
influenced by a combination of genetic, molecular, and environmental factors [1]. PD is
an irreversible and slow progressing disorder involving both motor and non-motor
symptoms such as sleep disorders, loss of smell, depression, and skin problems [2]. PD is
the second most common neurodegenerative disorder associated, with selective
degeneration of dopamine-producing neurons in the substantia nigra pars compacta
(SNpc) [3]. The appearance of Lewy Bodies (LB) is a pathological hallmark of the
disease and was first discovered by Frederic Lewy in 1912. These LBs are abnormal
aggregation of proteins mainly alpha-synuclein (-syn), that cause an array of issues for
neuronal cells, ultimately leading to cell death [4]. PD affects over 5 million individuals
worldwide, and over 1% of the US population over the age of 60. This number is grossly
underestimated because of the limitations we currently have diagnosing this disease.
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1.2. Symptoms
PD is characterized by both motor and non-motor symptoms, but most individuals are
diagnosed when characteristic motor symptoms appear. It has been shown that by the
time motor symptoms occur, 60-80% of dopaminergic neurons have already been
compromised severely limiting treatment options [5]. Parkinsonism is a syndrome
characterized by tremor, bradykinesia, rigidity, and postural instability [6]. These four
cardinal signs are what physicians currently use to diagnose patients with suspected PD
along with the clinical history of the patient and a possible DaTSCAN.
Tremor is the most common and well-known symptom of the four major motor
symptoms. Tremor is defined as a rhythmical, involuntary oscillatory movement of a
body part [7]. Resting tremor is developed at the onset of the disease and worsens as PD
progresses [8]. Making an accurate diagnosis of tremor disorders is challenging, since
similar disorders such as essential tremor (ET) and dystonic tremor can all cause
misdiagnosis [9]. Tremors are more common in arms compared to legs and the frequency
of these tremors is usually 4-6 hertz [10].
Bradykinesia is characterized by reduction in spontaneous movements giving an
appearance of stiffness. This stiffness and reduction in movement affects a patients
ability to perform daily tasks such as writing, brushing teeth, and getting dressed [10].
There are a range of issues that are related to bradykinesia, however in most cases the
principal deficit is that movements are slow. Several factors contribute to bradykinesia
such as muscle weakness, tremor, rigidity, and the primary factor is due to insufficient
recruitment of muscle force during initiation of movement, this results in patients’
movements undershoot their targets [11].
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Rigidity is a hypertonic state characterized by constant resistance throughout
range of motion that is independent of velocity [12]. Rigidity is one of the physician’s
telltale sign that helps them diagnose PD. It is caused by loss in muscle tone accompanied
by extreme stiffness [8]. Further, rigidity is often asymmetric but affects the entire body
as the disease progresses. This can lead to problems with achiness or pain in the muscles
or joints affected. Many people with PD will have reduced arm swing when walking,
more so on the most affected side. It has also been shown that rigidity negatively impacts
sleep quality due to pain making it hard to fall or stay asleep [13].
Postural instability refers to imbalance and loss of ability to stand upright. This
loss of reflex and imbalance leads to frequent falls, which may cause bone fractures [8].
Postural instability has been identified as a feature of late-stage PD, and considered one
of the most important criteria for diagnosing and categorizing PD patients [14]. These
motor impairments are caused by dopaminergic neuronal deficits [15]. One study found
that about 38% of patients experience falls due to instability and the frequency of falls
increases with severity of the disease [16]. These falls are the most common reason for
emergency room visits and largest motor related contributor to health care costs in PD
patients [17].
There are also some non-motor symptoms associated with PD, which include
sleep disorders, psychosis, dementia, depression, hallucinations, and mood disorders to
name a few [8]. Gastrointestinal (GI) issues such as constipation and excessive saliva, as
well as loss of smell, are also observed in patients especially during the early stages of
the disease, and usually antedate the first occurrence of motor signs [18]. In 2003, Braak
et al. hypothesized that an unknown pathogen in the gut could be responsible for the
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initiation of sporadic PD [3]. Braak postulated that sporadic PD starts in two places: the
neurons of the nasal cavity and the neurons in the gut causing the spread of -syn via the
vagus nerve and olfactory bulb [19]. The Braak hypothesis has also received criticism
due to the fact that not all PD patients follow the proposed staging system. The mean age
of onset is 60, however some cases appear between the ages of 20-50 [10]. Some studies
point to PD being more common in men as compared to women [20].

1.3. Four factors influencing PD pathogenesis
The exact cause for the onset of PD is still unknown, however there are many risk factors
associated with developing PD. It is unlikely that a single factor contributes to PD,
instead a multitude of factors such as age, genetics, environmental factors, and many
molecular factors such as protein aggregation, autophagy, and mitochondrial dysfunction
most probably act in concert.
Age is usually one of the major factors when it comes to neurodegenerative
diseases [21], and PD is characterized as an age-related disorder. The risk of developing
idiopathic PD after the age of 60 increases dramatically. This age-related risk is due to a
multitude of factors which include the inherent weakening of the neuronal cellular repaid
system [22], as well as increased genetic mutations. Neuronal protein aggregation
represents a hallmark of PD pathogenesis and proteosome dysfunction may contribute to
the increased susceptibility of developing PD [23]. Mitochondrial dysfunction also
increases with age and can lead to increased levels of reactive oxygen species (ROS) [24]
which has damaging cellular effects contributing to PD.
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Genetics also play an important role in both idiopathic and familial PD. Most PD
cases are sporadic, however approximately 10% of cases are familial or genetic [25].
Mutations in genes such as Leucine-rich repeat kinase 2 (Lrrk2), PTEN-induced putative
kinase 1 (PINK1), a-syn and Htra serine peptidase 2 (Park13) are all associated with PD
onset and progression [26, 27]. Autosomal recessive forms of early-onset PD are caused
by mutations in Parkin (PARK2) [28], and PTEN-induced putative kinase 1 (PINK1)
[29], both Parkin and PINK1 lead to mitochondrial dysfunction through the E3-ubiquitin
ligase pathway [30]. Despite extensive studies the molecular and genetic pathways
leading to the onset and progression of PD are poorly understood.
Environmental factors have also been shown to have a causative role in the onset
of PD. For example, paraquat (1’-dimethyl-4-4’-bypyridinium dichloride) has been
associated with PD where subjects, usually farmers associated with this pesticide, have an
increased risk of developing PD [31]. Paraquat causes an increase in ROS levels leading
to increased oxidative stress in neurons [32]. Insecticides and Organochlorides, such as
dieldrin, have also been shown to increase the risk of developing PD [33]. Interestingly,
some studies have also suggested that metal toxicity is correlated with the risk of
developing PD [34]. Indeed, one finding showed that postmortem PD brains had
increased iron levels [34], and that this elevation could in turn cause an in increase in
oxidative stress ultimately leading to cell death. Metal toxicity alone does not necessarily
increase the risk of developing PD, however coupled with other contributing factors it
may increase the occurrence of PD.
Molecular factors contributing to the onset of PD include protein aggregation,
oxidative stress, and autophagy and are described in more detail in the following sections.
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However, as a high level summary all of these factors contribute to proteostasis
dysfunction in cells.

1.3.1. Protein Aggregation
The aggregation of disease-specific proteins is a hallmark of many neurodegenerative
disorders. The presence of pathological aggregates, often called bodies or inclusions,
certainly classify both PD and AD. In most cases these pathological aggregates result
from the accumulation of misfolded and damaged proteins. In PD, LBs are enriched in syn and this aggregation has been correlated with inappropriate protein misfolding, and
protein accumulations. -syn proteotoxicity has traditionally be attributed to LB
formation in neurons. However, more recent studies have emerged suggesting that
smaller non-fibrillar, multimeric species of -syn are more significant to PD
pathogenesis [35, 36]. These multimers interact with and damage cell membranes [37].
Inappropriate autophagy is also implicated in the abnormal protein accumulation and
aggregation of proteins such as SNCA as cells age. Proteosome dysfunction is also
responsible for accumulation of aggregated proteins such as a-syn due to its inability to
clear misfolded proteins [38].

1.3.2. Oxidative stress
Oxidative stress is the major source of mitochondrial dysfunction, which is caused either
by dysfunctioning mitochondria producing more ROS or the inabilty to sustain proper
regulation of ROS [39]. The consequences of oxidative stress are overarching and
devastating to the cell; due to its deleterious effects oxidative stress is a key element to
6

elucidating the link between neurodegenerative diseases and age [39]. Oxidative stress
can alter transcription and translation of disease proteins by reacting with transcription
factors or altering enzymes respectively. Neurons combat oxidative stress by employing a
battery of antioxidant proteins called Peroxiredoxins involved in regulating H2O2 levels
[40]. Oxidative stress contributes to neuronal cell death in PD due to a gradual decrease
of the cells ability to cope with cellular damage over time [41].
Several key PD-associated proteins are linked to mitochondrial function and ROS
regulation such as, PINK1, PARK13, Parkin, and -syn. PINK1 along with Parkin
regulates mitophagy in response to mitochondrial dysfunction. PARK13, also activated
by PINK1, is a protease, which removes damaged mitochondrial proteins [42]. PARK13
mutations have been associated with oxidative stress and PD phenotypes, while
overexpression and knockout mouse models have shown both neuroprotection and PD
phenotypes [43, 44]. The accumulation of a-syn on the outer and inner membranes of
mitochondria in dopaminergic neurons decrease mitochondria complex 1 activity and
induced ROS levels [45]. Furthermore, mitochondria are fundamental regulators of
apoptosis, which makes oxidative stress-induced mitochondrial dysfunction an important
factor in relation to both PD and aging [46].

1.3.3. Autophagy
Autophagy is a cellular process that involves the efficient and selective degradation of
misfolded/ aggregated proteins [47]. Autophagy is a lysosomal-mediated degradation
pathway that is activated under stress conditions to degrade and eliminate damaged
organelles and proteins [48]. The process of autophagy is driven by a group of
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autophagy-related proteins (ATGs) that are responsible for autophagosome formation,
vesicle expansion, infusion with the lysosome, and cargo recruitment [49]. A complex of
protein kinases initiates the signaling mechanism that controls the activation of
autophagy, one of which is the mammalian target of rapamycin (m TOR) [50]. Defects in
autophagy are associated with the pathogenesis of many neurodegenerative diseases and
controlled modifications of autophagy may prove very useful in the development of
possible therapeutics [51]. Autophagy provides a clear link to PD and aging due to the
decline in cells ability to properly remove misfolded and aggregated proteins [44]. The
pathogenic mutations of -syn A30P and A53T have been shown to block the uptake of
damaged proteins or substances by the lysosome [52]. This inhibition is one of the key
aspects in the pathogenesis and progression of PD. It appears therefore that as neurons
age the susceptibility to develop PD increases based on reduced autophagy and clearing
of misfolded proteins such as SNCA. Indeed, mice deficient in the Autophagy-related
proteins ATG5 and ATG7 show accumulation of ubiquitinated aggregated proteins
causing neuronal stress and ultimately leading to cell death [53]. Another example is
illustrated by mitochondrial dysfunction where enlarged mitochondria do not get
removed by mitophagy [54]. The loss of function of mitophagy is caused by elevated
ROS levels and decreased lysosomal-autophagic degradation resulting from mutations in
DJ-1, a protein involved in cellular protection against oxidative stress [55]. Indeed,
enlarged mitochondria are often observed in PD subjects, possibly resulting from the
fusion of damaged mitochondria and compromised mitophagy [54]. This enlarged mass is
not observed in healthy subjects which show a 30% decrease in mitochondrial mass [56].
Combined these results point to the importance of autophagy, a regulated and orderly
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recycling of unnecessary or dysfunctional components of the cell. This process needs to
be tightly regulated by chaperones and proteins to maintain cellular homeostasis.

1.4. Clinical significance
Despite extensive research in the field the exact processes that contribute to the onset of
PD is poorly understood. Similarly, there has been no test formulated to correctly
diagnose PD. This presents a unique opportunity where combining research strategies
such as cellular assays and miRNA technology may lead to the identification of new
targets and pathways that could act as potential biomarkers for the identification of PD.
There is no biochemical test available to accurately diagnose PD, and patients often have
to visit multiple physicians and perform multiple tests to diagnose [57]. The most
effective drug to treat PD symptoms is dopamine replacement with Levodopa (L-Dopa),
which was discovered in the 1960s. This treatment is only effective for a short period of
time and also has severe side effects such as motor dyskinesia and increased oxidative
stress caused by metabolites of dopamine [58] . There is a great need to establish novel
pathways for potential therapeutics and drug design, as well as the development of
biomarkers for diagnostic purposes as well as monitoring disease progression.

1.5. miRNAs
miRNAs are a class of non-coding RNAs, 22 nucleotides in length, that play important
roles in gene regulation. Among all regulatory molecules, miRNAs are the most studied,
particularly as regulators in human diseases [59]. Most miRNAs are transcribed from
DNA sequences into primary miRNAs (Pri-miRNA) and processed into precursor
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miRNAs (Pre-miRNAs) and mature miRNAs [60]. Pri-miRNAs are transcribed from
miRNA-encoding genomic sequences by RNA polymerase II [61, 62], and they are then
processed into pre-miRNAs by the microprocessor complex, consisting of and RNA
binding protein DiGeorge syndrome critical region 8 (DGCR8) and ribonuclease III
enzyme drosha [63]. Once pre-miRNAs are generated they are exported to the cytoplasm
by exportin 5 and then processed by dicer [63]. This processing involves the removal of
the terminal loop, resulting in a mature miRNA duplex [64]. The directionality of the
miRNA strand determines the name of the mature miRNA strand. For instance, the 3p
strand originates from the 3’ end and the 5p strand originates from the 5’ end of the premiRNA hairpin [65]. miRNAs are proposed to be downregulators of gene expression via
two mechanisms: A). mRNA cleavage and B). translational repression. Through mRNA
cleavage the miRNA binds to complementary regions of protein-coding mRNA
sequences resulting in RNA induced silencing complex (RISC) cleavage [66].
Alternatively, and in the absence of appropriate complementarity, miRNAs also have the
ability to bind to 3’UTRs and block translation [66]. Intriguingly, miRNAs do not solely
function as target-specific regulators but may play key roles in post-transcriptional
reduction of expression [67].
Many studies have noted circulating miRNAs in biological fluids such as plasma,
serum, cerebrospinal fluid, saliva, and breast milk to name a few [68-71]. These
extracellular miRNAs are highly stable resisting degradation at room temperature, high or
low pH, and multiple freeze thaw cycles [72]. Extracellular miRNAs can be either found
in vesicles such as exosomes and microvesicles [73] or associated with proteins such as
Argonaute (AGO2) [70]. The presence of miRNAs in vesicles or with proteins is thought

10

to protect miRNAs and increase stability in extracellular fluid [70]. It is now accepted
that extracellular circulating miRNAs can play important roles in intracellular
communication also serving as potential biomarkers for disease.

1.6. A-syn
A-syn is primarily expressed in neuronal tissues and is linked genetically and
neuropathologically to PD. A neuropathological hallmark of PD is the presence of LB
which are insoluble aggregates enriched in the a-syn protein [74]. The SNCA gene
encodes for an 140 amino acid protein that does not have a defined structure and whose
function is not fully understood. In 1997, SNCA became one of the first reported genetic
aberration linked to PD [26]. The mutation corresponded to substitution in the SNCA,
resulting in an A53T amino acid change in the a-syn protein [26]. The pattern of
inheritance was autosomal-dominant and the disease was early-onset, generally around
the age of 40. Soon after two more autosomal dominant pathogenic SNCA mutations were
also discovered, A30P and E46K [75, 76]. In 2003, an SNCA triplication event was
reported, resulting in a two-fold increase in a-syn protein levels, which could ultimately
lead to development of PD [77].
A-syn may contribute to PD in multiple ways but it is generally thought that its
protofibrils are the toxic species that mediate disruption of the cellular homeostasis and
neuronal death [78]. Furthermore, secreted a-syn may exert deleterious effects on
neighboring cells including seeding of aggregation, possibly contributing to the
pathogenesis of PD [79]. Although genetic and biochemical studies are revealing
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important aspects of a-syn with respect to PD, it is still unclear how changes in SNCA/asyn influences disease onset and progression.

1.7. Parkin
Parkin is an E3 ubiquitin ligase which ubiquitinates mitochondrial proteins and targets
them for proteasomal degradation [30]. Mutations in Parkin cause loss of E3 ligase
function, and account for the second most common cause of PD [28]. Parkin plays an
important role in Familial PD due to genetic defects in Parkin causing autosomal
recessive PD. PINK1 acts upstream of Parkin and is required for Parkin activation and
recruitment to depolarized mitochondria [80]. Parkin gets selectively recruited to
damaged mitochondria and brings about ATG5-dependent mitophagy by recruiting
ubiquitin and p62 to mitochondrial membrane [81]. Parkin overexpression acts as a
protective agent reducing proteotoxicity in dopaminergic neurons [82].
Parkin has also been shown to prevent cell death through proteasomal degradation
of certain aggregated proteins such as SNCA. The exact mechanism of how over
expression protects against proteotoxicity is unknown, but it seems to be dependent on its
E3 ligase activity [83]. Mitochondrial deficits are also very prevalent in Parkin deficient
patients where decreased lymphocyte mitochondrial complex I is observed [84], and this
has also been observed in Parkin-knockout mice which show oxidative stress and
mitochondrial dysfunction [85]. Numerous mutations throughout the PRKN gene are
linked to autosomal recessive PD which is associated with early-onset PD [86], making
examination of Parkin crucial to understanding the pathogenesis of PD.
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1.8. ATG5
Autophagy is a highly conserved homeostatic process from yeast to mammals that
involves degradation of certain intracellular molecules and organelles [87]. Autophagy is
a tightly regulated process with 41 Autophagy-related proteins [88]. The autophagy
pathway plays an important role in the pathological process of neurodegenerative
diseases like PD. Autophagy related gene 5 (ATG5) plays an important role in initiation
and vacuole formation in autophagy [89]. Knocking down ATG5 can result in
downregulation or inhibition of autophagy suggesting that ATG5 plays an essential role
in autophagy, and thus ATG5 is one of the most targeted genes in autophagy gene editing
assays [90]. ATG5 initiates the formation of the autophagosome membrane and the
fusion of autophagosomes and lysosomes functioning in both canonical and noncanonical autophagy. ATG5 has been shown to play a protective role in neurons
displaying synucleinopathies and ATG5 deficiencies led to deficits in motor function
with accumulation of cytoplasmic inclusion bodies in the neurons of mice [91].
Autophagy is essential to the clearing of misfolded/aggregated proteins, therefore
disruption in the initiation or any steps can lead to cell death. One finding displayed that
ATG5 acted as a protective mechanism in zebrafish induced with the compound 1methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) a mitochondrial toxin [92]. MPTP is
a standard compound used to establish PD models in vitro and in vivo causing damage to
dopaminergic neurons [93]. ATG5 downregulation along with treatment impacted the
progression of PD and PD-related markers, however when ATG5 was overexpressed it
showed a restorative function and reversed the pathological progress of PD [92]. In
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patients with PD, ATG5 protein levels were altered, which suggests that ATG5 may
serve as a PD-related marker and risk factor [94].

1.9. Ataxin-3
Post-translational modification of proteins is central to regulating stability and activity.
One important modification involved in cellular homeostasis is ubiquitination which
involves tagging proteins for degradation [95]. Ataxin-3 (ATXN3) is a deubiquitinating
enzyme involved in protein quality control and is involved in removing ubiquitin from
proteins prior to degradation so that the ubiquitin may be recycled [96]. It’s known
activities include regulating the action of E3 ligases, participating in proteasomal
substrate delivery, and regulating aggresome formation [97]. Mutations in SCA3, the gene
encoding ataxin-3 causing repeat expansion causes spinocerebellar ataxia-3 (SCA3), the
most common inherited ataxia worldwide [98]. PolyQ diseases are age-related,
progressive disorders that typically first manifest in midlife, leading to death 15-30 years
later [99]. A common neuropathological hallmark in SCA3 is the accumulation of
ubiquitin-positive nuclear inclusions in neurons [100]. It has been reported that patients
with SCA3 have been shown to present parkinsonian symptoms [101]. Recent studies
have shown that ataxin-3 interacts with Parkin [102] and mutations in ATXN3 can
deubiquitinate parkin directly and reduce the extent of parkin ubiquitination in cells
[102]. The poly (Q) expansion mutant form of ataxin-3 promotes parkin degradation by
autophagy. Ataxin-3 has not been directly linked to PD however its interaction with
parkin and hinderance of parkin to properly ubiquitinate proteins for degradation has
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been linked to parkinsonian phenotypes. Thus, a deeper understanding of Ataxin-3
function and relationship to PD is important in further explaining the pathogenesis of PD.

1.10. BAG5
Misfolding, aggregation, and aberrant accumulation of proteins are hallmarks of many
neurodegenerative diseases including PD. Chaperones and cochaperones help guide and
execute protein folding as well as shuttling proteins that are destined for degradation
[103]. The Bcl-2 associated athanogene 5 (BAG5) is a co-chaperone known to act in both
cell survival and cell death pathways. Bag5 has been shown to interact with HSP70
molecular chaperone as well as Parkin [104], and this interaction with Parkin hinders its
function in mitophagy resulting in cell death [105]. It has been shown that BAG5 delays
parkin recruitment to mitochondria following mitochondrial depolarization, therefore
impairing mitophagy and enhancing cell death [105]. The mechanism by which BAG5
impedes Parkin recruitment to mitochondria is not clear however and is in direct
contradiction to Bag2 which enhances Parkin’s recruitment to mitochondria [104]. It has
been reported that physiological stress increases BAG5 expression [106] however
conflicting evidence has shown that BAG5 can either play a neuroprotective role as well
as a neurotoxic role.
BAG5 has been demonstrated to directly interact with PINK1, and regulated
PINK1 degradation via the UPS, and in addition protected mitochondria against MPP+
[107]. These findings suggested that BAG5 played an important role in stabilizing PINK1
by decreasing the ubiquitination of PINK1. Upregulation of BAG5 has also been shown
to inhibit apoptosis and increase expression of anti-apoptotic proteins in PC12 cells
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induced with MPP+ an apoptosis inducer [108]. Lastly, BAG5 has also been shown to
interact with DJ-1 and reduces the level of DJ-1 dimers in the mitochondria, which
suggests that BAG5 inhibits mitochondrial translocation of DJ-1 [109]. The role BAG5
plays in neurodegeneration is yet to be revealed due to conflicting evidence of its role
within the cell.
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2.0. Specific aims
The primary objective of this research is to achieve a deeper understanding of pathways
that contribute to neuronal cell death in PD, examine the relationship between PD-related
proteins, and discover the involvement of miRNAs in PD.
Specific aims include:
1. Evaluate and verify specific protein targets of miRNA candidates involved in PD.
2. Investigate what role miR-335-5p and miR-3613-3p play in the regulation of key
PD related proteins.
3. Examine whether elevated levels of miRs in PD patients play a neuroprotective or
neurotoxic role in neurons.
4. Investigate the regulation of ATG5, ATXN3, and BAG5 by miR-335-5p and
miR-3613-3p, and how they relate to PD pathogenesis.

17

2.1. Materials and Methods
Buffers
Universal buffers and their composition used in various protocols are listed below.
Specific buffers are described together with the specific protocols.

Lysis buffers
The recipes for the lysis buffers used during this dissertation are given here.
Following is the list of protein localization and lysis buffer used:
Protein Localization
Buffer recommended
Whole cell
NP-40 or RIPA
Cytoplasmic (soluble)
Tris-HCl
Cytoplasmic (cytoskeletal
Tris-Triton
Bound)
Membrane bound
NP-40 or RIPA
Nuclear
RIPA
Mitochondria
RIPA
Please consult separate protocols for sub-cellular fractionation.
Nonidet-P40 (NP40) buffer
150mM NaCl, 1% NP-40, 50mM Tris at pH8.0, and 2mM EDTA

Radio Immuno Precipitation Assay buffer (RIPA)
150mM NaCl, 1% NP-40, 50mM Tris at pH 8.0, 0.5% Sodium deoxycholate, and 0.1%
Sodium
Dodecyl sulfate (SDS).
Tris-HCl buffer
20mM Tris-HCl, pH 7.5
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Tris-Triton buffer
100mM NaCl, 1% Triton X-100, 10mM Tris at pH 7.4, 0.5% Sodium deoxycholate, 0.1%
SDS,
10% Glycerol, 10mM EDTA, and 10mM EGTA.

Western Blot analysis buffers
The recipes for buffers used for western blot analysis including buffers required for
pouring
Polyacrylamide gels are listed below.
Table 1.1. SDS Polyacrylamide gel recipe
Component
Deionized water (DIW)
30% Acrylamide
1.5M Tris Buffer pH 8.8
0.5M Tris Buffer pH 6.8
10% SDS
10% APS
TEMED

Stacking gel
4%
6.15ml
1.25ml
2.5ml
100ul
50ul
10ul

Resolving
gels
8%
4.73ml
2.67ml
2.5ml
100ul
50ul
5ul

12%
3.4ml
4ml
2.5ml
100ul
50ul
5ul

15%
2.4ml
5ml
2.5ml
100ul
50ul
5ul

20%
730ul
6.67ml
2.5ml
100ul
50ul
5ul

30% Acrylamide solution is 29.2% acrylamide and 0.8% N’,N’-bis-methyleneacrylamide.

Tris Buffer (1.5M at pH 8.8, 0.5M at pH 6.8)
Tris base 54.46g and 18.15g was dissolved in DIW; pH was adjusted with 6N HCl to 8.8
and 6.8
Respectively to make up the volume to 300ml with DIW.
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Running buffer (10X) and Transfer buffer (10X)
Stock solutions (10X) for running and transfer buffers were prepared with 3.84M Glycine
and
0.5M tris base. For running buffer 2% SDS was added.

Tris Buffer Saline (TBS) (10X)
TBS stock solution (10X) was prepared by dissolving 160.1g NaCl and 48.45g tris-HCl;
pH was
adjusted to 7.6 with HCl to make a 2L stock solution.

For TBS-T: 100ml of TBS (10X) + 900ml ultra-pure water + 1ml Tween20

Bacteriological Techniques
Bacterial Strains
E.coli DH5; (FS/endA1 hsdR17(rkSmk+), supE44, thi1, recA1, gyrA(Nalr),
gyrA96(Nalr),
relA1, Δ(lacZYA=argF) U169, deoR (Φ80dlac Δ(lacZ) M15)) was used For propagation
and
preparation of plasmid DNA.
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Vectors
pJET 1.2/blunt (Appendix. A) (Thermo Fischer Scientific) was used for routine
subcloning and
DNA manipulations.
pcDNA3 (Appendix A-) (Thermo Fischer Scientific) was used for heterologous protein
expression and stable cell line generation in mammalian cells.

Growth media and growth conditions
Bacteria were grown using Lysogeny broth (LB-1% Tryptone, 0.5% Yeast extract, and
1%
NaCl) in liquid cultures or LB-agar (1.5% agar added to LB) as colonies. Super optimal
broth
With catabolite repression (SOC – 2% Tryptone, 0.5% Yeast extract, 0.02% KCl, 0.25%
MgSO4
and 0.06% NaCl, and 036% Glucose; pH 7.0) was used during transformation for
recovery of transformants. Liquid cultures for DH5 were grown in a shaking incubator
at 250rpm at 37C. Colonies were grown on LB-agar plates incubated overnight (O/N) in
an incubator at 37C. Colonies were picked using sterile pipette tips and added to culture
tubes for growing liquid cultures with antibiotic selection.
Antibiotic Selection
Antibiotic selection was carried out to select colonies ad grow cultures of positive clones.
Antibiotics were added to medium prior to use (LB) or before pouring plates (LB-agar).
Ampicillin (100g/ml) was used as selection marker for pJET 1.2/blunt, pcDNA3
vectors; Kanamycin (50g/ml) was used for pET-28a(+) vector.
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Cloning
Primers
Primers used for various cloning experiments as well as semi-quantitative PCR and qRTPCR experiments are listed below (Table). Restriction endonuclease cutting sites are
underlined and in italics, and mutations are in bold/codon is underlined, if applicable.
Table 1.2. List of Primers

No.

Name of Primer (RE site/Tag)

Sequence with RE site & Tag

1)
2)
3)
4)
5)
6)
7)
8)
9)
10)
11)
12)
13)
14)
15)

pcDNA3 forward (100bp MCS)
pcDNA3 reverse (MCS100bp)
pJET1.2 forward (_MCS)
pJET1.2 reverse (MCS_)
scaRNA17 forward
RNA U6 forward
cel-miR-39-3p forward
hsa-miR-335-5p forward
hsa-miR-3613-3p forward
hsa-miR-6865-3p forward
hsa-miR-4797-5p forward
hsa-miR-455-3p forward
hsa-miR-3910-1 forward
hsa-miR-16-2-3p forward
hsa-miR-937-5p forward

CGCAAATGGGCGGTAGGCGTGTACG
TGGCACCTTCCAGGGTCAAGGAAGG
CGACTCACTATAGGGAGAGCGGC
AAGAACATCGATTTTCCATGGCAG
AGAGGCTTGGGCCGCCGAGC
CGCTTCGGCAGCACATATAC
ATTCACCGGGTGTAAATCAGC
ATTCAAGAGCAATAACGAAAAATGT
ATACAAAAAAAAAAGCCCAACC
ATACACCCTCTTTCCCTACC
ATGACAGAGTGCCACTTACTG
ATGCAGTCCATGGGCATATAC
ATTGCTGTCAGTTTTTCTGTTGC
ATCCAATATTACTGTGCTGC
ATGTGAGTCAGGGTGGGGC
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Polymerase Chain Reaction (PCR)
PCR was performed to amplify genes of interest from cDNA, and to screen for colonies
of positive transformants by colony PCR.
PCR to amplify genes for subsequent cloning:
Phusion DNA polymerase (Thermo Fischer Scientific) was used to amplify genes or
gene products due to its high-fidelity and to get accurate, blunt ended PCR products
which were first used for cloning into the shuttle vector pJET 1.2 vector.
PCR reactions were setup as follows:
Component

1x reaction (μl)

5x Phusion HF buffer
10mM dNTPs
Phusion DNA Polymerase
Forward primer
Reverse Primer
Vector
DIW

4
0.2
0.2
1
1
1
12

Reactions were setup with the following program:

Step
1
2
3

Temp. (ºC)
98
98
49

4

72
Goto step 2,
30x
72
4

5
6
7

Time
1min.
30sec.
30sec.
30sec/kb of PCR
product

7min
Forever
23

PCR to screen for bacterial colonies
Taq PCR Master mix kit (Qiagen, Inc.) was used to perform colony PCR for screening
positive transformants. Colonies were grown on LB-agar were picked using sterile pipette
tips and added to culture tubes with LB media and appropriate antibiotic selection.
Cultures were grown O/N at 37C in an incubator at 250rpm. 1l of liquid culture was
used as template in each PCR. Specific primer pairs (Table) were used to either confirm
the presence and/or orientation of gene product. The reactions were setup as follows:

Component
PCR Master Mix (2X)
Forward Primer
Reverse Primer
Cultures/colony
DIW

1x reaction (μl)
10
1
1
1
7

Reactions were setup with the following program:

Step
1
2
3
4
5
6
7

Temp. (ºC)
95
94
58
72
Goto step 2,
34x
72
4

Time
2min.
1min.
1min.
1min.

5min.
Forever
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Nucleic acid isolations
All DNA isolations were performed using commercial kits following manufacturer’s
protocol. GeneJET plasmid miniprep kit (Thermo Fischer Scientific) was used for small
scale routine isolation of plasmid DNA. QIAquick PCR purification kit (Qiagen) was
used to clean up the PCR product to remove components of the PCR mix to obtain
purified DNA product for further experiments. GeneJET Gel Extraction kit (Thermo
Fischer Scientific) was used to clean up the PCR product to remove primer dimers, and
other non-specific DNA bands.
Nucleic acid measurement
Nucleic acid in the form of plasmid DNA, genomic DNA, and cDNA were always, at
various stages, ran on agarose gels or NanoDrop 2000 Fluorospectrometer (Thermo
Fischer Scientific) for quality control (QC) purpose.
Nucleic acid manipulation
pJET cloning
All genes were first cloned by blunt end cloning into the pJET 1.2 vector using the
CloneJET PCR cloning kit (Thermo Fischer Scientific) according to the manufacturer’s
protocol. Ligated products were transformed into E. coli DH5- cells and colonies were
grown under ampicillin selection, and screened for positive transformants using
ampicillin selection.
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Restriction endonuclease digestions
Restriction endonuclease digests were performed as follows:
Component (per
reaction)

(μl)

Water (Nuclease free)
10X FastDigest buffer
DNA
Enzyme 1
Enzyme 2
Time 30min

3
1
5
0.5
0.5
Temp 37℃

Vector

Restriction
Endonuclease

pJET 1.2

BgIII (2 sites)

pcDNA3

RE flanking the
gene
of interest
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Ligations
Ligation (Thermo Fischer Scientific) reactions were setup as follows:
Component
Digested insert
Digested Vector (1050ng)
T4 DNA ligase
10X T4 DNA ligase buffer
Nuclease free water
Total

(μl)
8
0.5
0.5
1
0
10

Ligation mix was incubated at RT for 20-30mins. Ligation mix was used for
transformations.
Bacterial Transformations
DH5- cells were thawed on ice and typically 5l of the ligation reaction was added to
the cells. The transformation mix was incubated on ice for 30min. At the end of the
incubation, cells were subjected to heat shock at 42C for 45sec. Immediately followed
by incubation on ice for 2-3min. 900l SOC or LB media was then added to the cells and
the cells were incubated at 37C for 1hr with shaking. Cells were plated onto appropriate
LB-agar plates (antibiotic selection). The LB-agar plates were incubated at 37C for at
least 16hrs but no more than 20hrs.
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Characterization of bacterial transformants
Bacterial transformants were generally analyzed by two methods mentioned below.
Positively transformed colonies were verified by DNA sequencing at the Yale DNA
analysis facility, CT. The sequencing data was analyzed using BLAST by NCBI.
Colony PCR for colony screening
1l of O/N liquid bacterial culture were used for PCR reactions and the remaining was
used for subsequent DNA isolation. PCR reactions were setup using the Taq PCR Master
Mix Kit (Qiagen) and the primer pairs either flanking the MCS in vector, Flanking the
gene of interest or one internal primer along with vector specific primer. Samples were
run on a 1% agarose gel and colonies that gave the correct sized DNA fragment was used
for further analysis.
Agarose gel electrophoresis
PCR products or restriction digests were analyzed on 1% agarose gel electrophoresis. The
products were mixed with loading buffer (6X Loading buffer. 30% glycerol, 0.25%
bromophenol blue) and ethidium bromide in order to visualize the separated DNA
fragments on a UV transluminator. Tris-acetate-EDTA buffer was used to make the gels
and also running buffer. The gels were prepared by adding the appropriate amount of
agarose to 1X TAE buffer (40mM Tris base, 20mM Glacial acetic acid, and 1mM EDTA
at pH 8.0) followed by melting the agarose by heating in a microwave oven, adding
ethidum bromide, pouring into a gel cassette and allowing agarose gel to solidify. HiLo
DNA marker (Minnesota Molecular) was used as a size reference (Appendix).
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RNA processing and analysis
RNA isolation
Total RNA was extracted using specialized kits following the manufacturer’s protocol.
All the RNA samples were quantified and quality controlled on a Nanodrop 2000
(Thermo Scientific, MA).
RNA isolation (mRNA from mammalian cells)
All RNA isolations were performed 24hrs post-transfection or from stable cells in
triplicate. Total RNA was extracted from mammalian cells by using the RNeasy Mini kit
(Qiagen) and GeneJET RNA purification kit following manufacturer’s protocol. Total
RNA (enriched small RNA) was isolated using the miRCURY RNA isolation kit- cell
and plant (Exiqon).
RNA isolation (Small RNA from mammalian cells)
All RNA isolations were performed 24hrs post-transfection in triplicate. Total RNA was
extracted from mammalian cells using the miRCURY RNA isolation kit – cell and plant
(Exiqon) following manufacturer’s protocol.
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cDNA synthesis
All RNA samples were treated with 1 unit/g of RNA of DNase-1 (Thermo Scientific)
for 30min at 37C followed by 10min at 65C with 50mM EDTA. The DNase 1-treated
RNA was used to synthesize first strand cDNA using a variety of commercial kits.
cDNA synthesis (from mRNAs)
The DNase 1-treated RNA was used to synthesize first-strand cDNA, by using the
RevertAid First Strand cDNA Synthesis kit and an oligo dT primer (Thermo Fischer
Scientific) following the manufacturer’s instructions. The cDNA samples were used for
PCR amplifications of genes of interest for cloning, semi-qualitative PCR, and qRT-PCR.
cDNA synthesis (From small RNAs)
For small RNAs, cDNA was synthesized using DNase 1-treated RNA and the qScript
miRNA cDNA synthesis kit (Quanta Biosciences) following manufacturer’s protocol.
The cDNA samples were used for semi-quantitative PCR and qRT-PCR.
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Reactions were setup as follows in two steps:
Poly(A) Tailing reaction

Component
Poly(A) Tailing Buffer
(5X)

Per reaction (uL)
2

RNA (up to 1ug total)
Nuclease free water
Poly(A) Polymerase

up to 7uL
Variable
1

Mix components from above and incubate at 37C for 60mins followed by 5mins at
70C. Centrifuge and keep on ice for cDNA synthesis.
First strand cDNA synthesis reaction

Component
Poly(A) tailing reaction
(from previous step)
microRNA cDNA
Reaction Mix

Per reaction (uL)
10

qScript Reverse
Transcriptase

1

9

Incubate reaction mix for 20mins at 42C followed by 5mins at 85C, and allow to
gradually come down to 4C. Store at -20C for future expression analysis.
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Semi-quantitative RT-PCR (mRNA and small RNAs)
cDNA was used for semi-quantitative RT-PCR using appropriate primer pairs (Table)
and PCR protocol for 25 cycles. The samples at the end of the reactions were run on 1%
agarose (for mRNAs). The gel images were analyzed at the end, to semi-quantitatavely
measure gene expression. GAPDH (mRNAs) and U6 (small RNAs) were used as controls
in all the semi-quantitative RT-PCR experiments.
Real-time qPCR
Equal amount of cDNA in each sample was used to perform qRT-PCR. All qRT-PCR
were performed using PerfeCTa SYBR GREEN SuperMix for IQ containing
AccuStart Taq DNA polymerase (Quanta Biosciences) for 45 cycles followed by
dissociation steps with a MyiQ single color Real-time PCR detection system (Bio-Rad,
CA). No template control (NTC) was employed.
Reaction was setup as follows:

Component
PerfeCTa SYBR Green
Supermix (2X)

Per reaction (uL)
25

PerfeCTa microRNA
Assay Primer (10uM)
PerfeCTa Universal PCR
Primer (10uM)
Nuclease Free water

1
1
23
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Real-time qPCR (mRNA)
For mRNA qRT-PCR, gene specific primers, at a concentration of 1uM were used. The
qRT-PCR protocol was as follows: Intial denaturation at 95C for 2mins followed by 35
cycles of denaturation at 95C for 15s, annealing at 60C for 45s and extension at 72C
for 40s. GAPDH or Actin was used as reference RNAs for normalizing Cq values to
calculate relative expression.
Real-time PCR (Small RNA)
qRT-PCR for small RNA quantification were performed with reaction volume of 20l
with small RNA-specific forward primers and a PerfeCTa Universal PCR primer at a
final concentration of 0.2uM. The qRT-PCR protocol involved initial denaturation at
95C for 2min followed by 45 cycles of denaturation at 95C for 15s, annealing at 60C
for 30s and extension at 72C for 15s, which was followed by dissociation steps of 0.5C
increments. scaRNA and U6 were used as reference small RNAs for normalizing Cq
values whereas cel-miR-39-3p was used as spike-in control. The standard curve for celmiR-39-3p was anaylzed in MS excel with R2 = 0.97882 and PCR efficiency 92.96%.
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Tissue culture and processing
Tissue culture guidelines:
Table 1.3 Tissue Culture Guidelines

Conversion chart used for tissue culture experiments. Invitrogen.
Cell culture and stock information
Sh-SY5Y cells were cultured in a base medium (1:1 mixture of DMEM/Ham’s-F12)
(Invitrogen) supplemented with fetal bovine serum (FBS) (Atlanta biologics) at a final
concentration of 10% and 2mM GlutaMax (Invitrogen) in a 5% CO2 atmosphere at 37C.
BE-M17 cells were maintained in the same way. Cells were sub-cultured every 4-5 days
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to maintain confluency. Full medium supplemented with 5% DMSO was used as freezing
medium to cryopreserve cells.
Transfections
The transfection experiments were performed the day after seeding, for each plasmid
transfection, 0.5g plasmid DNA was diluted with 50l Opti-MEM (Life technologies,
Grand Island, NY) and 1.25l Lipofectamine 2000 (Invitrogen) was diluted with 50l of
Opti-MEM and incubated for 5min at RT. After incubation both solutions were mixed
and incubated for 15mins at RT. This transfection mix was diluted to 2ml with OptiMEM and added to cells for transfection. Cells were incubated at 37C in 5% CO2
atmosphere for 4-6hrs. before replacing with full media. Appropriate empty vector
controls were used with each transfection experiment. The cells were used 24hr (RNA)
and 48hr (Protein) after transfection and incubation for downstream processing.
Transfection (miRs)
The day after seeding cells were transfected using scrambled control mimic/inhibitor and
mimic/inhibitor of miR-335-5p, miR-3613-3p, and miR6865-5p obtained from
mirVana (Life Technologies), at a final concentration of 20nM. 2l of each RNA
(20M stock), was diluted with 100l of Opti-MEM and 7l of Lipofectamine RNAiMax
(Invitrogen) was diluted with 100l of Opti-MEM and incubated for 5min at RT. The two
solutions were then mixed together and incubated for 15min at RT. The transfection mix
was diluted to 2ml with Opti-MEM, added to the cells and incubated at 37C in 5% CO2
atmosphere for 4-6hrs before replacing with full media. Cells were harvested after 24hr
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for transcript analysis by qRT-PCR and after 48hr for protein analysis by Western
Blotting.
Cell Treatments
All treatments were performed in serum-free complete media at 37C for 6hr, unless
indicated otherwise. Untreated cells were maintained in serum-free complete media at
37C for 6hr as well. Various reagents used for treatments are given in the table below.
Table 1.4. Cellular Treatments
Reagent

Concentrations used

Supplier

H2O2

100μM

J.T. Baker, Center
Valley, PA

L-3,4-dihydroxyphenylalanine (L-DOPA)

100μM

Acros, Pittsburgh, PA

Rotenone

1μM, 10μM, 50μM

Sigma Aldrich

6 hydroxydopamine (6OHDA)

1μM, 10μM, 100μM

Sigma Aldrich

Cell Harvesting
Cells growing at 85-90% confluency were trypsinized and removed from the plate. Cell
suspension was spun down by centrifugation at 500xg at 4C for 5min, supernatant was
discarded and cells were washed with 1ml ice cold PBS and spun down again.
Supernatant was discarded and lysis buffer (RIPA) was added to cell pellet, pipetting up
and down to break up the pellet. Centrifuge tube was kept on ice for 10mins, followed by
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a spin at max speed (25,000xg) for 10min. Supernatant was collected and placed in
another labeled centrifuge tube and kept at

-20C for future processes.

Protein analysis
Western blot analysis
Western blot analysis was performed using the following protocol:
Sample preparation: Protein lysates were always thawed on ice and 5x reducing dye was
added to samples followed by boiling at 95C for 5min. Samples were than cooled on ice
for 1min, and subjected to quick centrifugation to collect condensate.
SDS-PAGE and Blotting: Whole cell lysates were generally prepared using RIPA buffer.
Protein estimation was performed using the DC Protein assay kit (Bio-Rad, Hercules CA)
showing <10% variation in protein concentrations among the same fractions. 4l of 5x
Laemmli sample buffer (50mM Tris pH 6.8, 0.1% SDS, 20% glycerol, 0.2%
bromophenol blue) with BME was added to 16l of whole-cell lysates. Samples (20l)
were subjected to SDS-PAGE by using the mini-Protein Tetra system (Bio-Rad) with
12% polyacrylamide slab gels at 100V for 90min in running buffer (192mM glycine,
25mM Tris Base, 0.2% SDS). The separated proteins were transferred to PVDF
membranes (Pall Life Sciences, Ann Arbor, MI) in transfer buffer (192mM glycine,
25mM Tris Base, 20% methanol, and 0.005% SDS) at 200mA for 45min, followed by
blocking in 5% nonfat dry milk/TBS-T (137mM NaCl, 15.4 mM Trizma HCl, 0.1%
Tween 20, pH 7.6) for 1 hour at RT. After blocking the membrane was incubated with
the appropriate primary antibody at 1:1000 dilution (unless otherwise indicated) in 2.5%
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nonft dry milk overnight at 4C and washed with TBS-T three times for 10min. After
wash appropriate secondary antibody (Jackson Immunoresearch, West Grove, PA) at
1:10,000 dilution for 1hr at RT. The membrane was washed with TBS-T three times for
10min each. The membrane was developed using the Pierce ECL Western blot substrate
(Therno Fischer Scientific) and signal detection was recorded with the molecular imager
Chemi Doc XRS1 imaging system (Bio-Rad). PageRuler Unstained Broad Range
Protein Ladder, which has each protein containing an integral Strep-tag II Sequence, was
used as a marker for all the gels and blots.
Table 1.5. List of Primary and Secondary antibodies
Antibody (Dilution used 1:1000 for
primary and 1:10000 used for
secondary
1)
2)
3)
4)
5)
6)
7)
8)
9)
10)
11)
12)
13)
1)
2)
3)
4)

Primary Antibodies
Rabbit polyclonal anti-GAPDH
Mouse monoclonal anti-PARKIN
Rabbit polyclonal anti-ATXN3
Mouse polyclonal anti-BAG5
Rabbit polyclonal anti-ATG5
Rabbit polyclonal anti-SOD1
Rabbit polyclonal anti-GBA
Goat polyclonal anti-Park13
Rabbit polyclonal anti-SNCA
Rabbit polyclonal anti-LRRK2
Rabbit polyclonal anti-PINK1
Mouse monoclonal anti-DJ-1
Mouse monoclonal anti-Actin
Secondary Antibodies
Goat anti-Rabbit IgG (H+L)-HRP
Donkey anti-Goat IgG (H+L)-HRP
Goat anti-Mouse IgG (H+L)-HRP
Precision Protein StrepTactin-HRP

Vendor

Santa Cruz Biotechnology
Santa Cruz Biotechnology
Abcam
Santa Cruz Biotechnology
Santa Cruz Biotechnology
Santa Cruz Biotechnology
Santa Cruz Biotechnology
Santa Cruz Biotechnology
Abcam
Abcam
Novus Biologicals
Enzo Life Sciences
Santa Cruz Biotechnology
Jackson Immunoresearch
Jackson Immunoresearch
Jackson Immunoresearch
Bio-Rad
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Cell Viability assay
Cell viability was measured using the neutral red uptake assay 48hr post transfection.
Cells were washed with PBS, 100l of neutral red working solution (40g/ml) added to
each well and plates were incubated for 2hr. Cells were then washed with PBS, neutral
red extracted using 150l of destain solution (50% ethanol, 1% glacial acetic acid, 49%
deionized water) per well and the plates were subjected to shaking for 10min.
Absorbance was measured at 540nm using an Epoch microplate spectrophotometer
(Bioteck)
Breadford assay for protein estimation
Protein concentrations were measured using protein assay kit II and DC protein assay kit
(Bio-Rad, Hercules, CA) Bovine serum albumin was used to prepare incremental
standard solutions from 0.05-1.0mg/ml. Assays were performed in 96-well micro-plates
and the colormetric reading were recorded using Epoch microplate spectrophotometer
(Bioteck). Protein samples were diluted from 1:10 to 1:100 for the assay. Samples for
loading were prepared based on the concentrations obtained by the assay.
Image analysis and statistical analysis
ImageJ software (NIH, Bethesda, MA) and IQTL software (GE healthcare) was used to
analyze
Western blot as well as agarose gel images. All values represent mean values ± Standard
error
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unless indicated. Statistical analyses were performed using Microsoft excel unless
otherwise
mentioned, with students’ t-test, and p<0.05 is denoted as significant, unless mentioned
otherwise.
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Main Project: microRNA regulation of key PD proteins
Introduction
PD is the most common, progressive neurodegenerative movement disorder
characterized by the loss of dopaminergic (DA) neurons in the substantia nigra pars
compacta (SNpc) [110]. The etiology of PD has been linked to age, environmental
factors, and mutations in several genes including SNCA, Parkin, and PINK1 [111].
Aggregation of misfolded proteins causing inclusion bodies is a hallmark of PD [112].
The presence of LBs enriched in the protein a-syn plays a major role in neuronal cell
death enhancing the progression of Parkinson’s like neurodegeneration [113, 114]. The
E3 ubiquitin ligase Parkin plays a prominent role in both familial and sporadic PD,
although Parkin is neuroprotective and promotes neuronal cell survival its loss of
function causes mitochondrial dysfunction[115, 116]. Parkin, along with its associated
molecular chaperone HSP70, are found in LBs in sporadic PD [117]. BAG5 (bcl-2associated athanogene 5) is a member of the BAG family and has been shown to form a
complex with HSP70 [118], and interact with Parkin. This interaction has deleterious
functional consequences by inhibiting HSP70 chaperone activity and Parkin E-3 Ligase
activity causing an influx of protein aggregation [119].
Non-coding RNAs are involved in many regulatory cellular processes and make
up a significant portion of our genome. miRNAs are small non-coding RNAs which are
20-22 nucleotides in length and function in gene regulation and silencing [120]. miRNAs
have also been extensively studied as potential biomarkers due to their extracellular
stability and altered disease state expression [121] A recent study highlighted the
differences in miRNA levels from PD and non-diseased brains stating that miRNAs are
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differentially expressed in patients with PD allowing for classification of PD within a 5%
error [122]. While this is taking a potential diagnostic approach there have been studies
which show regulatory effects of miRNAs in PD. One specific study showed the
regulatory effects of miR-34b/c on the key Parkinson’s proteins Parkin and DJ-1 causing
loss in cell viability [123]. A considerable number of miRNAs have been reported for
their regulatory roles in PD [124]. We investigated miR-335-5p and miR-3613-3p which
have been associated with an array of diseases from cancer to gestational diabetes,
however there are no studies to date that show the relationship between miR-335-5p and
miR-3613-3p and PD.
In this study we show that miR-335-5p and miR-3613-3p levels are significantly
elevated in PD patients as compared to healthy individuals which further corroborated
our previous findings [125]. This increase in miRNA expression was also prevalent in
post-mortem frontal cortext samples for both PD and age-matched controls. We further
report that miR-335-5p and miR-3613-3p overexpression may have a neuroprotective
function as it increases cell viability in SH-SY5Y cells induced with oxidative stress. We
also show that oxidative stress causes miR-335-5p and miR-3613-3p overexpression not
seen under normal, non-stressed conditions. This increase leads to increased levels of
ATG5 and BAG5 whilst decreasing levels of ATXN3.
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Results
miR-335-5p and miR-3613-3p show upregulated expression in post-mortem PD
brains
In our previously reported longitudinal study we identified, verified and validated miR335-5p, miR-3613-3p, miR-6865-3p as differentially expressed in 370 PD (drug-naïve)
and control serum samples from the Norwegian ParkWest study and in 64 PD (drugnaïve) and control serum samples from NY Parkinsonism in UMeå (NYPUM) study
[125]. We further showed that that miR-335-5p, miR-3613-3p, miR-6865-3p
(PARKmiRs), and any two combinations of the PARKmiRs, were robust classifiers of
PD at baseline diagnosis [125].To expand on these findings and to gain insight into
whether the increased miRNA levels in serum may reflect changes in brain miR profiles
we isolated small RNAs from post-mortem frontal cortex brain samples of PD patients
and age matched healthy control individuals. RNA isolation was performed on 9 PD
brains and 6 age matched control brain samples, and expression levels were measured
using a SYBR Green-based quantitative reverse-transcriptase polymerase chain reaction
(qRT-PCR) assay. scaRNA17 was used as a small RNA reference for normalizing the
qRT-PCR Cq values and cel-miR-39-3p was used as a spike-in control. The spike in
control was included to ensure that recovery of small RNA was consistent across the
samples. The results from the qRT-PCR assay revealed that both miR-335-5p and hsamiR-3613-3p levels were significantly upregulated in PD brains (Fig.1) compared to
healthy age matched controls. We also tested six other PARKmiRs discovered in our
previous study [121] revealing that hsa-miR-6865-3p was also significantly upregulated
in PD brain samples, however for this study we will only focus on miR-335-5p and miR43

3613-3p. The finding that miR-335-5p and miR-3613-3p levels are elevated in frontal
cortex brain samples of PD patients, complements our previous data showing elevated
PARKmiRs levels in PD serum, possibly suggesting a mode of miR release into serum
from the brain.

Figure 1.1 Upregulation of PARKmiRs in brain samples. qRT-PCR comparison of

post-mortem frontal cortext brain samples of Parkinson’s patients and healthy agematched controls showing significant upregulation of PARKmiRs hsa-miR-335-5p, hsamiR-3613-3p, and hsa-miR-6865-3p in PD brain samples compared to control. All above
(n=4), * p < 0.05; ** p < 0.01; *** p < 0.001.
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Overexpression of miR-335-5p and miR-3613-3p increase cell viability in response
to oxidative stress
To investigate whether overexpression of miR-335-5p and miR-3613-3p has any
significant effect on cell viability we performed a neutral red assay on SH-SY5Y cells
overexpressing the two PARKmiRs, independently. To impose stress on the SH-SY5Y
cells we also treated cells with 100µM H2O2 and 100µM L-Dopa for six hours followed
by the neutral red assay. We observed no change in cell viability in SH-SY5Y cells
overexpressing a control mimic or the miR-335-5p and miR-3613-3p mimics (miR-335M
and miR3613M) in untreated cells as expected (Figure 2A). However, after six hours of
treatment with 100µM H2O2 we observed a significant loss in viability in cells expressing
the control mimic (Figure 2A). Interestingly, cells overexpressing miR-335-5p and miR3613-3p showed a significant rescue in cell viability as compared to the control mimic
expressing cells suggesting that both PARKmiRs may have a possible protective role
(Figure 2A). A similar result was also observed in response to 100µM L-Dopa treatment
(Figure 2A) suggesting that both PARKmiRs have a protective effect in response to
oxidative stress, either directly by H2O2 treatment or indirectly in response to L-Dopa
exposure.
This observed protective effects of both miR-335-5p and miR-3613-3p on SHSY5Y cells, in response to oxidative stress, may explain the elevated levels of both
PARKmiRs in PD serum [121] and PD brain samples (Figure 1). These elevated levels of
both PARKmiRs may indeed contribute to mitigating neurodegeneration in PD. To
further dissect this possibility, we first exposed wild-type SH-SY5Y cells to H2O2 and L45

Dopa in a dose dependent manner for six hours followed by cell viability analysis. We
observed, as expected, a progressive loss in cell viability with increasing concentration of
both H2O2 and L-Dopa (Figure 2B). We then performed qRT-PCR on the wild-type SHSY5Y cells exposed to 100µM H2O2 and 100µM L-Dopa for six hours, which showed
that both endogenous PARKmiRs are significantly upregulated in response to oxidative
stress as compared to untreated cells (Figure 2C). Combined these results suggest that the
elevated levels of miR-335-5p and miR-3613-3p in PD brains and PD serum may
positively contribute to a neuroprotective pathway in PD.
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Figure 2.1 PARKmiRs significantly increase cell viability in response to oxidative

stress.
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Neutral red assay and fluorescence image analysis showing significant increase in cell
viability in response to H2O2 and L-Dopa treatments in cells overexpressed with miRs.
(A) miR-335-5p and miR-3613-3p mimic overexpression shows significant rescue in cell
viability for SH-SY5Y cells treated with 100M H2O2 or 100M L-Dopa. (B) Dosedependent curve of control SH-SY5Y cells treated with H2O2 and L-Dopa showing
increased loss in cell viability with increasing concentrations of treatments. (C) qRT-PCR
expression of miR-335-5p and miR-3613-3p respectively showing significant increase in
expression in response to H2O2 and L-Dopa treatments. All above (n=4), * p < 0.05; ** p
< 0.01; *** p < 0.001.

Increased expression of miR-335-5p and miR-3613-3p has neuroprotective effects
As a hallmark of PD onset is the aggregation of a-syn and progression is directly
associated with missense mutations, duplication and triplication events in the a-syn
encoding gene SNCA [26] we wanted to more fully understand how miR-335-5p and
miR-3613-3p function in a neurotoxic environment similar to that observed in PD. To
this end we created SH-SY5Y cell lines that overexpressed wild-type a-syn triplication
mutation and the two clinical a-syn variants a-syn-A53T and a-syn-E46K point mutations
[76, 77]. To confirm overexpression of wild-type a-syn, a-syn-A53T and a-syn-E46K in
our stable SH-SY5Y cell models we performed western blot analysis using a monoclonal
anti-a-syn antibody. The western blot analysis showed that all three cell lines
overexpressed a-syn, a-syn-A53T and a-syn-E46K to a similar level showing significant
overexpression of the 14kDa a-syn monomer as compared to cells expressing the pcDNA
empty vector control (Figure 3A). To further determine the levels of endogenous miR48

335-5p and miR-3613-3p in the three a-syn cell models we performed miR extraction
from the cells followed by qRT-PCR analysis. Interestingly, we found that both miR-3355p and miR-3613-3p were significantly elevated in cells overexpressing wild-type a-syn
and in cells overexpressing the two clinical variants a-syn-A53T and a-syn-E46K as
compared to cells expressing pcDNA3 alone (Figure 3B).
Closer analysis of the data also revealed that the expression profiles of miR-3355p and miR-3613-3p differed between the different cell lines except for a-syn-A53T
where the expression of both PARKmiRs was similar (Figure 3B). It is unclear why the
expression profiles of miR-335-5p and miR-3613-3p differ between the different a-syn
mutant cell lines but it may be due to differences in severity of cellular toxicity caused by
the mutations. To further investigate whether overexpression of wild-type or mutated asyn has an effect on cell viability we performed neutral red assays on the three cell lines
and showed that overexpression of wild-type a-syn, a-syn-A53T and a-syn-E46K had no
significant effect on SH-SY5Y cell viability under normal conditions (Figure 3C).
As overexpression of wild-type a-syn, a-syn-A53T and a-syn-E46K, coupled with
exposure to oxidative stress such as H2O2 mimics the neurotoxic environment in PD, we
wanted to determine whether miR-335-5p and miR-3613-3p can act as neuroprotectors in
this PD simulated environment. To accomplish this we transfected miR-335-5p and miR3613-3p into SH-SY5Y cell lines overexpressing wild-type a-syn, a-syn-A53T and a-synE46K, respectively. Two days after transfection we treated cells with 100M H2O2 for
six hours and performed a neutral red assay to quantify cell viability. Our results show
that miR-335-5p and miR-3613-3p overexpression results in cell viability rescue for all
mutants compared to control cells (Figure 3D). Indeed, we did not observe this cell
49

viability rescue with only endogenous levels of miR-335-5p and miR-3613-3p implying
that overexpression of these two PARKmiRs is needed in order to positively effect cell
viability under neurotoxic stress conditions. These data suggest therefore that miR-3355p and miR-3613-3p are acting in a neuroprotective capacity perhaps by regulating genes
that confer neuroprotection in neurons.

Figure 3.1 PARKmiRs show increased cell viability under neurotoxic conditions.
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(A) Western blot analysis showing overexpression of monomeric -syn Lane’s 1-4:
pcDNA3, wt-SNCA (Triplication mutation), E46K, A53T. (B) Overexpression of
endogenous miR-335-5p and miR-3613-3p in mutant cell lines using qRT-PCR. (C)
pcDNA3, wt-SNCA, E46K, A53T cells were treated with neutral red and cell viability
was assayed (n=3, ns- no significance). (D) Indicated cells were treated with 100uM
H2O2 for 6 hours followed by neutral red assay for cell viability Lane 1-4, Untreated,
Treated, miR-335-5p treated, miR-3613-3p treated ( n=3, *p< 0.05, **p<0.01, t test).

ATG5, Ataxin-3, and BAG5 are all regaulated by miR-335-5p and miR-3613-3p
To identify potential targets of miR-335-5p and miR-3613-3p we used both in silico
prediction analysis (miRTarBase, Partek Genomics Suite) and our previously reported
LC-MS data [121]. From this analysis we identified 1,516 putative protein targets with
high enrichment scores for miR-335-5p and miR-3613-3p. This putative protein target list
was then further analyzed for proteins with known associations to neurodegenerative
pathways, PD, and other fundamental neuronal processes. We found that ATG5, Ataxin3, and BAG5 were all predicted targets of miR-3613-3p, however miR-335-5p did not
target any of these. These targets were of interest because of their direct correlation with
PD as well as other neurological diseases. We continued to investigate the regulation of
ATG5, Ataxin-3 (ATXN3), and BAG5 with respect to miR-335-5p because of its
previously recorded regulatory effects on Leucine Rich Repeat Kinase 2 (LRRK2) which
BAG5 has been shown to directly interact with [126]. Recently, ATG5 has been shown to
contribute to the protection of dopaminergic neurons in a MPTP zebrafish PD model
where ATG5 downregulation leads to decreased autophagy flux further resulting in an
51

influx of aggregated proteins [92]. This was only alleviated when ATG5 was
overexpressed in cells [111]. ATXN3 has also been shown to be involved in autophagy
where mutant ATXN3 causes downregulation of BECN1 resulting in decreased
autophagosome formation [127].
To further validate our in silico analyses we transfected the miR-335-5p and miR3613-3p into SH-SY5Y cells and confirmed overexpression of miRs with qPCR (Figure
4A), followed by western blot analysis for ATG5, BAG5 and Ataxin-3. We found that
both miR-335-5p and miR-3613-3p overexpression significantly upregulates the
expression of Atg5 compared to the control (Figure 4C). Bag5 also showed significant
upregulation in overexpressed miR-335-5p cells, however we did not observe any
significant regulation of Bag5 in cells overexpressing miR-3613-3p (Figure 4D-E).
Interestingly, miR-335-5p had a reverse regulatory effect on Atxn3 by significantly
downregulating its expression (Figure 4F). We observed a moderate, but significant
upregulation of Atxn3 in overexpressed miR-3613-3p cells (Fig 4G). It is certainly
interesting to note that overexpression of miR-335-5p had an effect on all protein targets
tested suggesting a possible expansive regulatory role miR-335 in these pathways. We
did not find significant alteration of ATG5, ATXN3, and BAG5 at the mRNA level
suggesting that a post-transcriptional mechanism was involved in the observed alterations
of these proteins.
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Figure 4.1 PARKmiRs 335 and 3613 significantly regulate expression of ATG5,
BAG5, and ATXN3.
(A) qRT-PCR analysis showing miR-335-5p and miR-3613-3p in response to mimic
microRNA transfection. Western blot analysis comparing Control mimic cells (1) with
miR-335-5p mimic (2) and miR-3613-3p mimic (3). (B, C) Western blot analysis
showing significant upregulation of ATG5 in both miR-335-5p & miR-3613-3p
overexpression. (D, E) Western blot analysis showing significant upregulation of BAG5
in cells overexpressing miR-3613-3p. (F, G) Western blot analysis showing significant
downregulation of ATXN3 in cells overexpressing miR-335-5p and significant
upregulation of ATXN3 with cells overexpressing miR-3613-3p. All above (n=4), * p <
0.05; ** p < 0.01; *** p < 0.001.
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Discussion
Mutations in ATG5, ATXN3, and BAG5 have been shown to enhance neurodegeneration
due to misfolded proteins [128], and these mutations have been noted in idiopathic PD
patients, suggesting that mutations in ATG5, BAG5, and ATXN3 are associated with PD
[92]. Previous studies have demonstrated that BAG5 functions as a nucleotide exchange
factor of Hsp70 and also interacts with Parkin to inhibit Parkin E3 ubiquitin ligase
activity which in turn inhibits Parkin’s ability to ubiquitinate misfolded proteins such as
alpha synuclein [129]. ATG5 has been shown to play a neuroprotective role in
dopaminergic neurons by increasing autophagy of misfolded and aggregated proteins.
This clearance of aggregated proteins mitigated its cytotoxic effects in the neuron [92].
ATXN3 repeat expansion mutations have been shown mainly in Spinocerebellar ataxia
type 3 (SCA3) a neurodegenerative disease in the cerebellum [130]. It has also been
shown to cause Parkinson’s like phenotypes and previous studies have found that repeat
expansion mutations occur in early-onset PD [131].
In our study, we have demonstrated that miR-335-5p and miR-3613-3p are
unregulated in PD post mortem brain samples corroborating our previous findings [125].
In cells over expressing miR-335 and miR-3613 we showed a neuroprotective function
and a rescue of cell viability when inducing SH-SY5Y cells with hydrogen peroxide
stress. Interestingly, we also found an increase in endogenous expression of miRs 335
and 3613 in our mutant cell lines over expressing a-syn variants further corroborating our
claims that miR expression is increased in neurotoxic conditions. Taking it one step
further when we overexpressed our miRs in mutant cell lines along with hydrogen
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peroxide stress we also found an increase in cell viability compared to the control. This
lead us to believe that miR-335 and miR-3613 are acting in a neuroprotective manner and
this could be a reason why we see overexpression of both miRs in serum, brain, and
mutant cell lines.
In conclusion, we report a novel role for miRs 335 and 3613 as modulators of
ATG5, ATXN3, and BAG5. We have also shown that overexpression of both miRNAs
resulted in an increase in cell viability under oxidative stress conditions. The
understanding of how these miRNAs regulate expression of key targets and the pathways
involved will lead to improved understanding of the pathogenesis of PD.

Future Work:

Future work would include analyzing the effect mutant versions of Ataxin-3 have on
Parkin and how it’s down-regulation by miR-335-5p ameliorates the negative effects
Ataxin-3 has on the cell.
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Review Project: Cellular Proteostasis in Neurodegeneration.
Introduction
Neurodegenerative disorders are progressive, debilitating diseases characterized by motor
and cognitive symptoms caused by neuronal death and dysfunction. Neurodegenerative
diseases such as Parkinson’s Disease (PD), Alzheimer’s Disease (AD), Huntington’s
Disease (HD), Amyotrophic Lateral Sclerosis (ALS) and prion diseases (pD) share
implicated risk factors such as oxidative stress, aging, environmental factors and protein
dysfunction [132]. These risk factors, however, manifest distinctly in each disease and
produce unique pathologies.
Protein misfolding and aggregation is a common theme amongst many
neurodegenerative diseases, therefore maintaining intracellular protein homeostasis
(proteostasis) by balancing protein folding and misfolding is paramount in protecting the
functionality of the proteome [133]. Misfolded proteins are generally inactive, but the
accumulation of these inactive misfolded proteins causes stress responses in cells and
organelles. The endoplasmic reticulum (ER) is a key organelle in the maintenance of
proteostasis; ER stress via protein accumulation triggers the unfolded protein response
(UPR). The UPR promotes correct protein folding and diminishes ER protein level by
proteosomal degradation, translation mitigation and autophagy [134]. Autophagy plays an
essential role in proteostasis because of its ability to degrade protein aggregates that cannot
be processed by the proteasome [135]. Indeed, the autophagosome can break down and
recycle whole organelles in an effort to promote cell survival. Protein degradation by
autophagy and the proteasome utilize ubiquitination to recruit target proteins
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[4]. Ubiquitination along with other covalent attachments such as phosphorylation,
SUMOylation, and oxidation regulate normal proteome function. Post-Translational
Modifications (PTMs) of proteins have been shown to facilitate aggregation in many
neurodegenerative diseases (NDs) [136].
A hallmark of NDs is the toxic accumulation and proteotoxicity of diseaseassociated proteins. Protein accumulation can lead to aggregates or inclusions, which may
be toxic or protective [137]. Proteotoxicity is especially problematic with respect to postmitotic neurons, drawing a clear line between neurodegeneration and age. Mitochondrial
proteostasis is also critical for cell survival. Its dysfunction can lead to accumulation of
reactive oxygen species (ROS), which can be disruptive to cellular proteostasis. ROS can
debilitate cellular processes by damaging DNA, RNA, lipids, and proteins; stress that
disturbs mitochondrial proteostasis may lead to the irreversible induction of apoptosis.
Apoptosis, a highly regulated set of pathways leading to cell death, is initiated in cells
under stress to avoid the damaging of adjacent cells; this, while advantageous to organisms
in most cases, is detrimental to the nervous system as differentiated neurons cannot be
reproduced. Although neuronal loss cannot be fully attributed to apoptosis, it is a common
culprit in many neurodegenerative disorders such as PD, AD, HD and ALS.
In this review, we describe important factors that can alter proteostasis and how
proteostasis dysfunction ultimately affects neurodegeneration.
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Aim of paper
To highlight the many factors that contribute to neurodegeneration such as posttranslational modifications, protein aggregation, ER-stress, and autophagy. The review
further aimed at describing how alterations in cellular proteostasis can lead to neuronal cell
death, and highlight the correlation between many neurodegenerative disorders.

Figure 1.2 Altered proteostatic levels and protein conformations lead to hallmark
pathological neurodegenerative pathways. Damaged and excessive protein directly causes
ER stress and aggregation as well as mitochondrial dysfunction and oxidative stress
indirectly. Additionally, feedback loops (I, II) highlight the destructive nature of damaged
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proteins propagating ER stress and mitochondrial dysfunction leading to loss of
functionality further altering proteostasis. The cellular defense response to these pathways
Includes proteosome degradation, autophagy/mitophagy, and apoptosis

Figure 2.2 Pathway of protein throughout the ER. Protein is synthesized in the rough ER
by ribosomes. Native protein is predominantly exported, while some can aggregate.
Misfolded protein aggregates are sent to proteasome for degradation. Misfolded protein
and aggregates promote the UPR,which includes UPR associated gene regulation, ERAD
pathway, chaperone response, and apoptosis all in an effort to mitigate the effects of toxic
aggregates
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Figure 3.2 Neurodegenerative disorders alter specific steps in the autophagic pathway,
which ultimately leads to neuronal cell death. The altered steps include reduced induction
levels due to protein aggregation and defective mTOR inhibition; Defects in cargo
recognition resulting in accumulation of toxic proteins; Mutation in VCP leads to
inhibited transport of autophagic vesicle in ALS; Defects in lysosome/autophagasome
fusion and acidification. All defective steps, leading to impairment of protein degradation
by lysosomal degradation, ultimately leads to the release of cathepsin’s and apoptosis.
Huntington’s disease (HD); Alzheimer’s disease
(AD); Parkinson’s disease (PD); spino-cerebelar ataxia (SCA); spino-muscular atrophy
(SMA); dementia with Lewy bodies (DLB); Amyotrophic Lateral Sclerosis (ALS);
Valsin-containing protein (VCP)
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Collaborative Projects
Effects of SNCA and disease-causing mutations on the proteome of SH-SY5Y
cells
SNCA aggregation and accumulation is a key part of PD pathology. It is however
unknown at what stage SNCA changes its fate and translocates to Lewy bodies. The
pathogenic mutations (A30P, E46K and A53T), in addition to duplication and triplication
events, make it worthwhile exploring what effect the expression of these pathogenic
forms of SNCA has on the proteome in dopaminergic neuronal SH-SY5Y cells. To this
end we have transfected pcDNA4 empty vector, and the pcDNA4 vector, containing
SNCA WT, SNCA A30P, SNCA E46K and SNCA A53T into SH-SY5Y cells. Stable cell
lines were selected by supplementing full media with zeocin. At this stage we have
extracted total protein from all the clones for 2D-gPAGE analysis and Western blot gels
have already been run and analyzed. The manuscript is ready for submission to Journal
of Neuroscience Research.

Contributions:
I worked with Rashed Abdullah on this project. I performed mammalian cell culture
maintenance, I performed western blot analysis for multiple replicates as well as control
samples. I also helped with image analysis of figures.
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Figure contribution: Performed replicates of western blots from Whole cell lysates.

Figure 1.3 Whole cells lysate results of transfections of pathological variants of SNCA as
well as wt-SNCA to mimic duplication/triplication event. Cells were transfected with
pcDNA3 as a transfection control; wt-SNCA to mimic a duplication/triplication event;
A30P-SNCA, E46K-SNCA, and A53T-SNCA to mimic the presence of the pathological form
of a-syn in cells. Cells were measured for cell survival with and without treatments.
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Western blot images are representative blots. a) Whole cells lysate of transfections of
pathological mutations under no treatments, H2O2, and L-Dopa treatments (n=3). b) An
assay of cell viability as measured by the neutral red assay. Cells were checked to determine
if the viability was affected by transfections of pathological mutants and by H 2O2 and LDopa treatments (n=3). We found no significant decrease in the viability of cell treated
with H2O2, and L-Dopa.

Alpha-Synuclein Multimerization is Dependent on Structural Characteristics
of Repeated KTKEGV Regions

A physio-pathological hallmark of PD is the presence of Lewy Bodies: aggregates which
are highly enriched in -syn. -syn is an intrinsically disordered protein that forms
soluble multimers, which may or may not contribute to its aggregation. Isolating critical
components of alpha-synuclein’s structure could lead to a therapeutic strategy of
preventing its aggregation. The repeated KTKEGV motif has been implicated as critical
to neurotoxicity and the presence of multimers or exclusive presence of monomers in
neuroblastoma cells. Targeting the repeated motif. KTKEGV, is a sensible approach to
studying the critical components of -syn proteostasis simply due to its prevalence
throughout the protein. We transfected BE(2)-M17 human neuroblastoma cells in order to
overexpress at similar levels alpha-synuclein containing mutations in the KTKEGV
motif. Western blotting was used to measure -syn multimeric distributions in whole cell
extracts. The data shows that physiological distribution of -syn multimers throughout
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neurons is cell-type specific and influenced by the sequence of repeated N-terminus
KTKEGV motifs. The manuscript is ready for submission to Journal of Biological
Chemistry.

Contributions:
I worked closely with Benjamin Rosen. I assisted with subcellular fractionations of
BE(2)-M17 cells, cell culture maintenance, and western blot analysis. I worked on
multiple replicates and loading controls.

Concluding Remarks
This study aims to both clarify the importance of the repeats sequence to alpha-synuclein
multimerization and aggregation in neurons as well as within subcellular compartments
of neurons.
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Figure 1.4 Subcellular fraction comparison of alpha-synuclein in M17D cells stably
overexpressing repeat mutant SNCA. (A, D) Cytosolic (B, E Membrane bound (C, F, I)
Nuclear soluble (G, H) Chromatin bound
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Review Project: The Intersection of Parkinson’s disease, viral
infections and COVID-19

The novel SARS-CoV-2 coronavirus (COVID-19) pandemic has caused a global health
crisis infecting millions worldwide. Along with flu-like symptoms (fever, chills, cough) a
large number of infected individuals also experience a host of neurological issues
including loss of smell and taste, dizziness, decreased alertness, and brain inflammation.
A striking number of symptoms including gut issues are also prevalent in PD. A higher
mortality rate has also been reported in patients with PD not only due to low age, but also
through interactions with the brain dopaminergic system and the inflammatory response.
The gut microbiota plays an important role in many processes outside of a healthy
digestive system. It has been shown to be essential in protecting against host pathogens
[138] and even plays a role in our psychological well-being [139]. Viral infections are
among some of the most common pathogens invading our gut microbiome causing
dysbiosis and a multitude of Gastrointestinal issues (GI)[140]. Patients with PD display
an array of GI complications such as constipation, dysphasia, and dysbiosis (Table) [141]
and these complications often occur years before hallmark motor symptoms arise [142].
The gut microbiota is also decreased in older adults due to a number of factors that
include diet, genetics, and environmental factors [143]. It has also been noted that severe
viral infections could possibly increase the risk of developing PD later in life [144]
although not the primary cause but merely a risk factor. Evidence has suggested that
SARS-CoV-2 RNA can be detected in the stool of some patients with COVID-19 [145].
This data suggests that there may be a link between the gut microbiota and COVID-19
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severity, particularly as the higher COVID-19 mortality rate is seen within the elderly
population that already have a decreased microbiota. This may also suggest an increased
chance of COVID-19 mortality for a patient with PD due to an increase of underlying
conditions which include a compromised Gut flora [146]. Revised manuscript
resubmitted to Molecular Neurobiology.

Concluding remarks
In this review we have highlighted the intersections between PD, viral infections and
COVID-19 with the emphasis on the many similarities between RNA viral pathways and
neurodegeneration in PD. Indeed, the onset and progression of PD, as detailed in the
Braak hypothesis, as well as the pathogenic nature, molecular mechanisms, and symptom
development of the disorder share many similarities with the SARS-CoV-2 virus and
COVID-19. As further research is conducted, more evidence of a possible correlation
between PD, Viral infections and the current SARS-CoV-2 virus will become available.

Parkinson’s
Disease

RNA Virus
Infection

Alphasynuclein
Aggregation
leads to
neurotoxic
Lewy Bodies
[4]

Oxidative Stress
Dysfunctional
regulation of ROS
by several genes
including SOD1
leads to oxidative
stress and
apoptosis [147]
Upregulated Can create ROS
in infected
imbalance causing
cells and
DNA damage and
restricts RNA neuroinflammation
virus
[156]
replication
[154, 155]

Inflammation
Protective short
term,
exacerbates
non-motor
symptoms long
term [148, 149]

Metals
Exposure to
heavy
metals such
as Mn is a
risk factor
for PD [150]

Neuroinflammatory
response can be
triggered by
infection [154,
157]

RNA virus
replication
depends on
and may
cause
increase in
Mn and Fe
[158, 159]

Gut
Microbiome
GI problems
such as
dysbiosis,
constipation,
and dysphasia
[151]

Olfactory
Tract
Olfactory
dysfunction
is one of
the earliest
signs of PD
[152, 153]

Microbiota
depletion leads
to GI issues
causing
inflammation
and lack of gut
flora [160]

Olfactory
dysfunction
is one of
the earliest
signs of
COVID-19
infection
[161, 162]

Table 1.6 Commonalities between Parkinson’s Disease and RNA virus infection
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Fig. 1.5 The Brain-Gut microbiota axis: Schematic diagram highlighting the relationship
between the brain and gut microbiota. A rich and diverse microflora allows for healthy
immune and regulatory mediators, whereby a compromised gut microflora caused by
viral infections, stress, and poor diet can cause a pro-inflammatory state with implications
for neuroinflammation.

68

Publications
Published and submitted manuscripts resulting from the research described.
1. Alberim Kurtishi*, Benjamin Rosen*, Ketan S. Patil, Guido W. Alves, Simon Geir
Møller (2018). Cellular Proteostasis in Neurodegeneration. Molecular Neurobiology,
56: 3676.
2. Alberim Kurtishi, Ketan S. Patil, Benjamin Rosen, Guido W. Alves, Simon Geir
Møller (2021). Neuroprotection by miR335 and miR3613 may involve regulation of
ATXN3, BAG5, and ATG5. Journal of Neuroscience Research. Submitted March
2021.
3. Benjamin Rosen, Alberim Kurtishi, Michael Padron, Ketan Patil, Francisco X.
Vazquez, Simon Geir Møller (2021) Alpha-Synuclein Multimerization is Dependent
on Structural Characteristics of Repeated KTKEGV Regions. Journal of Biological
Chemistry, Submission March 2021
4. Rashed Abdullah, Ketan Patil, Benjamin Rosen, Alberim Kurtishi, James Young,
Simon Geir Møller* (2021). Pathologic alpha-synuclein multimeric profiles in SHSY5Y neuroblastoma cells. Journal of Neuroscience Research. In preparation.
5. Benjamin Rosen, Alberim Kurtishi, Gonzalo Vasquez, Simon Geir Møller (2021).
The Intersection of Parkinson’s Disease, Viral infections and COVID-19. Molecular
Neurobiology submitted Jan. 2021

69

Appendix A: List of Vectors

Vector Maps were obtained from manufacturer’s website.
A-1. pJET 1.2/blunt
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A-2 pcDNA3
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Appendix B: Molecular size markers
B-1. PageRuler Unstained Broad Range Protein Ladder

B-2. Hi-Lo DNA Marker
Hi-Lo DNA Marker has approximately 935ng/10ul with DNA concentration per band
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